✨
AI Summary
- Monika Swietlicka discusses FDA's increased regulatory flexibility in CGT development.
- Emphasis on risk-based, holistic approaches without lowering evidentiary standards.
- Implications for developers, platform strategies, and global regulatory divergence.
Guests on This Episode
MS
Monika Swietlicka
3 podcast appearances